Larimar Therapeutics (LRMR) Stock Price, News & Analysis

Company Overview

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of next-generation immunotherapies using engineered exosomes as delivery vehicles. The company’s proprietary ExoIL-12 platform is designed to encapsulate and deliver interleukin-12 directly to the tumor microenvironment, aiming to enhance anti-tumor immune responses while minimizing systemic toxicity. In addition to its lead candidate, exoIL-12, Larimar is advancing ExoASO-STAT6, an exosome-encapsulated antisense oligonucleotide intended to reprogram immunosuppressive cells within solid tumors.

By leveraging a bioengineered exosome delivery system, Larimar aims to overcome longstanding challenges associated with cytokine therapy and oligonucleotide delivery. The company’s approach combines targeted biodistribution with controlled payload release, potentially enabling higher therapeutic doses and improved safety profiles. Larimar’s preclinical programs have demonstrated robust tumor infiltration and immune activation, supporting its ongoing phase 1 clinical trials for patients with advanced or metastatic solid tumors.

Founded in 2016 as a spin-out from research at the Massachusetts Institute of Technology, Larimar Therapeutics is headquartered in Cambridge, Massachusetts, with research and development operations in the Boston area. Under the leadership of President and CEO Glen Allcorn, the company has established collaborations with academic institutions and contract research organizations to advance its manufacturing and clinical development capabilities. Larimar continues to explore global partnerships to expand its pipeline and bring novel exosome-based therapies to patients in need.

Key Stats

• Today's Range: $3.13 to $3.40
• 50-Day Range: $1.79 to $3.48
• 52-Week Range: $1.61 to $10.37
• Volume: 750,782 shs
• Average Volume: 842,261 shs
• Market Capitalization: $212.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.50
• Consensus Rating: Buy

Larimar Therapeutics Stock Analysis - MarketRank™

Larimar Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 638th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Larimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Larimar Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Larimar Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Larimar Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Larimar Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.24% of the float of Larimar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Larimar Therapeutics has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Larimar Therapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Larimar Therapeutics does not currently pay a dividend.

Dividend Growth

Larimar Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.24% of the float of Larimar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Larimar Therapeutics has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Larimar Therapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Larimar Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

12 people have searched for LRMR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 17 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -19% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Larimar Therapeutics is held by insiders.

Percentage Held by Institutions

91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LRMR Stock Analysis - Frequently Asked Questions

How have LRMR shares performed this year?

Larimar Therapeutics' stock was trading at $3.87 on January 1st, 2025. Since then, LRMR shares have decreased by 14.2% and is now trading at $3.32.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its earnings results on Wednesday, April, 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.04.

Who are Larimar Therapeutics' major shareholders?

Top institutional investors of Larimar Therapeutics include Assenagon Asset Management S.A. (0.40%), Next Level Private LLC (0.03%) and Wealth Enhancement Advisory Services LLC (0.02%). Insiders that own company stock include James E Flynn, Michael Celano, Joseph Truitt and Frank E Thomas.
View institutional ownership trends.

How do I buy shares of Larimar Therapeutics?

Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Larimar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Larimar Therapeutics investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LRMR
• CIK: 1374690
• Web: larimartx.com
• Phone: (844) 511-9056
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Larimar Therapeutics: $18.50
• High Price Target: $26.00
• Low Price Target: $10.00
• Potential Upside/Downside: +464.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -52.48%
• Return on Assets: -46.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.48
• Quick Ratio: 7.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.69 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 64,028,000
• Free Float: 61,147,000
• Market Cap: $209.69 million
• Optionable: Optionable
• Beta: 0.86